If you’re familiar with immunomodulatory compounds, you’ve likely heard of itaconate – a metabolite derived from the Krebs cycle that’s gained traction for its anti-inflammatory and antioxidant properties. But its cell-permeable derivative, dimethyl itaconate (DMI), is stepping into the spotlight with a groundbreaking new role: inhibiting angiogenesis, the formation of new blood vessels that’s critical for both normal development and disease progression. A 2022 study published in the International Journal of Molecular Sciences (PMCID: PMC9783644) is the first to confirm DMI’s anti-angiogenic potential, opening doors for novel treatments for conditions like cancer, psoriasis, and autoimmune diseases. Let’s dive into the details of this exciting research.
The Backstory: Why DMI and Angiogenesis Matter
First, let’s set the stage. Angiogenesis is a double-edged sword. In healthy bodies, it’s essential for wound healing, tissue repair, and fetal development. But when it runs amok, it fuels diseases: tumors rely on new blood vessels to grow and spread, while excessive angiogenesis contributes to psoriasis, age-related macular degeneration, and chronic inflammation. For decades, researchers have hunted for compounds that can “turn off” abnormal angiogenesis – and DMI, already known for its therapeutic promise, has emerged as an unexpected candidate.
DMI is no stranger to medical research. As a membrane-permeable form of itaconate, it’s been shown to fight inflammation by targeting pathways like NF-κB and activating the Nrf2 antioxidant response. It’s also demonstrated efficacy in animal models of psoriasis, sepsis, and even liver cancer, with minimal toxicity to vital organs like the heart and liver. But here’s the gap the new study fills: while DMI’s anti-inflammatory effects hinted at potential links to angiogenesis (inflammation and angiogenesis are closely intertwined), no one had directly tested whether DMI could block the key steps of blood vessel formation – until now.
The Study: How Researchers Tested DMI’s Anti-Angiogenic Power
Led by a team from the University of Málaga (Spain) and supported by Spanish research grants, the study focused on endothelial cells – the building blocks of blood vessels. The researchers used two common cell models: bovine aortic endothelial cells (BAEC) and human umbilical vein endothelial cells (HUVEC), ensuring the findings were relevant to both animal and human biology.
To mimic angiogenesis in the lab, the team designed a series of experiments targeting the four critical steps of blood vessel formation:
- Cell proliferation: Endothelial cells must divide rapidly to form new vessels.
- Migration: Cells must move to the site of new vessel growth.
- Invasion: Cells must penetrate surrounding tissue to form functional vessels.
- Tube formation: Cells must organize into tube-like structures – the foundation of blood vessels.
They also tested whether DMI affected cell cycle progression or the secretion of matrix metalloproteinases (MMPs), enzymes that help endothelial cells break down tissue during invasion (MMP-2 is particularly key for angiogenesis).
The Big Findings: DMI Blocks Angiogenesis at Every Step
The results were clear: DMI inhibits angiogenesis in a dose-dependent manner, targeting all four critical steps without causing harmful side effects like cell death. Here’s the breakdown:
1. DMI Stops Endothelial Cell Growth
When treated with DMI, both BAEC and HUVEC showed reduced proliferation. The half-maximal inhibitory concentration (IC50) – the dose needed to cut cell growth by 50% – was 276 ± 53 μM for BAEC and 491 ± 76 μM for HUVEC. These concentrations are in the “submillimolar” range, similar to other known anti-angiogenic compounds, making DMI a viable candidate for therapeutic development. Follow-up experiments with EdU (a marker for DNA synthesis) confirmed that DMI directly inhibits cell division, not just cell survival.
2. DMI Prevents Tube Formation (the “Final Step” of Angiogenesis)
On Matrigel – a gel that mimics the body’s extracellular matrix – BAEC normally form tube-like structures within hours. But DMI disrupted this process:
- 500 μM DMI reduced tube formation to just 33% of the control group.
- 250 μM DMI reduced it to 63%.
- Only the lowest dose (125 μM) had no significant effect.
This is a crucial finding because tube formation is the hallmark of functional angiogenesis – without it, new blood vessels can’t form.
3. DMI Slows Endothelial Cell Migration
Using a “wound healing” assay (where cells migrate to close a scratch in a cell layer), the team found that 500 μM DMI drastically reduced migration: after 8 hours, only 25% of the wound was closed, compared to 67% in the control group. Lower doses (250 μM and 125 μM) also slowed migration, though less dramatically. For angiogenesis, slow migration means endothelial cells can’t reach the site where new vessels are needed.
4. DMI Blocks Invasion – But Not MMP-2 Secretion
In a Transwell assay (measuring cell invasion through a Matrigel-coated membrane), all tested DMI doses (125–500 μM) significantly inhibited BAEC invasion. Surprisingly, though, DMI didn’t affect the secretion of MMP-2 – an enzyme critical for breaking down tissue during invasion. This suggests DMI uses a unique mechanism to block invasion, separate from MMP-2 regulation.
5. DMI Doesn’t Disrupt the Cell Cycle or Induce Apoptosis
Unlike some anti-angiogenic drugs that kill cells or halt the cell cycle (which can cause side effects), DMI had no impact on BAEC’s cell cycle distribution (G1, S, G2/M phases) or apoptosis (cell death). This is a major advantage: it means DMI targets angiogenesis specifically, without harming healthy cells.
Why This Matters: DMI’s Unique Advantages and Future Potential
What makes DMI stand out from other anti-angiogenic compounds? Let’s compare it to dimethyl fumarate (DMF) – a similar Nrf2 activator used to treat psoriasis and multiple sclerosis. Both DMF and DMI have anti-angiogenic effects, but DMI has a key difference: it doesn’t alter the cell cycle or induce apoptosis. This makes DMI potentially safer, as it’s less likely to cause off-target effects on healthy tissues.
Additionally, DMI’s known anti-inflammatory and immunomodulatory properties could make it a “double-edged therapy” for diseases where inflammation and angiogenesis go hand-in-hand. For example:
- Psoriasis: DMI’s anti-angiogenic effects could complement its existing anti-inflammatory action, addressing both the inflammatory and vascular components of the disease.
- Cancer: Tumors rely on angiogenesis to grow and metastasize. DMI could block this process while also modulating the tumor microenvironment (via its anti-inflammatory effects) to reduce cancer progression.
- Autoimmune diseases: Conditions like experimental autoimmune encephalomyelitis (EAE, a model for multiple sclerosis) involve blood-brain barrier damage and abnormal angiogenesis. DMI has already been shown to protect the blood-brain barrier in EAE – its anti-angiogenic effects could enhance this protection.
What’s Next for DMI?
While this study is groundbreaking, it’s just the beginning. The researchers note that future work should focus on:
- In vivo testing: Confirming DMI’s anti-angiogenic effects in animal models of diseases like cancer or psoriasis.
- Mechanism of action: Uncovering exactly how DMI blocks angiogenesis – especially its MMP-2-independent invasion inhibition.
- Clinical trials: Evaluating DMI’s safety and efficacy in humans, either alone or in combination with existing therapies.
Final Thoughts
The discovery that DMI is a potent, selective anti-angiogenic compound is a game-changer. It builds on DMI’s already impressive track record as an immunomodulator and opens new avenues for treating diseases driven by abnormal angiogenesis. What’s most exciting is DMI’s unique profile: it targets all key steps of angiogenesis without disrupting the cell cycle or inducing apoptosis, making it a safer alternative to some current therapies.
As research progresses, we may soon see DMI move from the lab to the clinic – offering hope for patients with conditions where angiogenesis is a critical driver. For now, this study reminds us that nature’s metabolites (and their derivatives) hold endless potential for drug development – and that connecting seemingly unrelated biological pathways (like immunomodulation and angiogenesis) can lead to breakthroughs.
If you’re working in angiogenesis, immunology, or drug development, keep an eye on DMI – this compound is just getting started.